Goldman Sachs initiated coverage of Sionna Therapeutics (SION) with an Early-Stage Biotech designation. Lead assets SION-719 and SION-451 are ...

Improving economic conditions and a more favorable regulatory environment give Goldman Sachs catalysts to benefit from in the ...

Barclays downgraded shares of Moderna (NASDAQ:MRNA – Free Report) from an overweight rating to an equal weight rating in a report published on Tuesday, Ratings reports. The firm currently has $45.00 ...

China is starting to see a rebound in M&As as government stimulus measures start to bear fruit and pressure from Donald Trump ...

EPS estimates but beats revenue expectations. Barclays downgrades stock, citing COVID demand decline and RSV uptake ...

Goldman Sachs raised its forecast to $3,100/oz from $2,890 on central bank buying and inflows into exchange-traded funds in a note Monday, while Morgan Stanley has a forecast of $2,700.

Learn More The gold price rose to a new record above US$2,940 per ounce last week, and top broker Goldman Sachs reckons this safe-haven asset has more room to run this year. The Australian ...

In a report released on February 14, Luca Issi from RBC Capital maintained a Hold rating on Moderna (MRNA – Research Report), with a price ...

CSL and Cochlear are two of Australia’s blue-chip healthcare stocks, stalwarts of many investors portfolios, whereas Pro Medicus is likely either a relatively new addition, or is on many investors’ ...

Feb 17 (Reuters) - Goldman Sachs on Monday raised its year-end 2025 gold price forecast to $3,100 per ounce, up from $2,890, citing sustained central bank demand. The bank estimates that ...

New orders also cascaded 16.4 points lower, though were still positive at 17.8. Barclays downgraded Moderna shares to equal weight from overweight, citing heightened policy uncertainties and limited ...

Looking ahead to 2025, Moderna expects revenue of $1.5 to $2.5bn. Credit: Tada Images/Shutterstock. Moderna has reported revenue of $1bn for the fourth quarter (Q4) of 2024 – a sharp decline from the ...